Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C32H38N2O8.ClH |
Molecular Weight | 615.114 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 6 / 6 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
Cl.[H][C@]12C[C@@H](OC(=O)C3=CC(OC)=C(OC)C(OC)=C3)[C@H](OC)[C@@H](C(=O)OC)[C@@]1([H])C[C@@]4([H])N(CCC5=C4NC6=C5C=CC=C6)C2
InChI
InChIKey=YCNOGQOHKRDAHJ-UZXCFUCJSA-N
InChI=1S/C32H38N2O8.ClH/c1-37-24-12-17(13-25(38-2)29(24)39-3)31(35)42-26-14-18-16-34-11-10-20-19-8-6-7-9-22(19)33-28(20)23(34)15-21(18)27(30(26)40-4)32(36)41-5;/h6-9,12-13,18,21,23,26-27,30,33H,10-11,14-16H2,1-5H3;1H/t18-,21+,23-,26-,27+,30+;/m1./s1
Molecular Formula | ClH |
Molecular Weight | 36.461 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
Molecular Formula | C32H38N2O8 |
Molecular Weight | 578.6527 |
Charge | 0 |
Count |
|
Stereochemistry | ABSOLUTE |
Additional Stereochemistry | No |
Defined Stereocenters | 6 / 6 |
E/Z Centers | 0 |
Optical Activity | UNSPECIFIED |
DescriptionSources: https://www.drugbank.ca/drugs/DB01089
Sources: https://www.drugbank.ca/drugs/DB01089
Deserpidine is an ester alkaloid drug isolated from Rauwolfia canescens (family Apocynaceae) with antipsychotic and antihypertensive properties that has been used for the control of high blood pressure and for the relief of psychotic behavior. Rauwolfia alkaloids work by controlling nerve impulses along certain nerve pathways. As a result, they act on the heart and blood vessels to lower blood pressure. Deserpidine's mechanism of action is through inhibition of the ATP/Mg2+ pump responsible for the sequestering of neurotransmitters into storage vesicles located in the presynaptic neuron. The neurotransmitters that are not sequestered in the storage vesicle are readily metabolized by monoamine oxidase (MAO) causing a reduction in catecholamines.
CNS Activity
Originator
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL1893 Sources: https://www.drugbank.ca/drugs/DB01089 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Sources: https://www.drugbank.ca/drugs/DB01089 |
Primary | HARMONYL Approved UseFor the treatment of hypertension. Launch Date1957 |
Cmax
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
172 pg/mL |
0.25 mg single, oral dose: 0.25 mg route of administration: Oral experiment type: SINGLE co-administered: |
DESERPIDINE plasma | Homo sapiens population: HEALTHY age: UNKNOWN sex: UNKNOWN food status: UNKNOWN |
AUC
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
4193 pg × h/mL |
0.25 mg single, oral dose: 0.25 mg route of administration: Oral experiment type: SINGLE co-administered: |
DESERPIDINE plasma | Homo sapiens population: HEALTHY age: UNKNOWN sex: UNKNOWN food status: UNKNOWN |
T1/2
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
42.9 h |
0.25 mg single, oral dose: 0.25 mg route of administration: Oral experiment type: SINGLE co-administered: |
DESERPIDINE plasma | Homo sapiens population: HEALTHY age: UNKNOWN sex: UNKNOWN food status: UNKNOWN |
Doses
Dose | Population | Adverse events |
---|---|---|
6 mg 3 times / day multiple, oral (max) Highest studied dose Dose: 6 mg, 3 times / day Route: oral Route: multiple Dose: 6 mg, 3 times / day Sources: Page: p.1115 |
unhealthy n = 13 Health Status: unhealthy Condition: Schizophrenia Sex: M Population Size: 13 Sources: Page: p.1115 |
PubMed
Title | Date | PubMed |
---|---|---|
Inhibition of capacitative calcium entry is not obligatory for relaxation of the mouse anococcygeus by the NO/cyclic GMP signalling pathway. | 2001 Feb |
|
Extensive skinning of cell membrane diminishes the force-inhibiting effect of okadaic acid on smooth muscles of Guinea pig hepatic portal vein. | 2002 Apr |
|
CaM kinase IIalpha mediates norepinephrine-induced translocation of cytosolic phospholipase A2 to the nuclear envelope. | 2003 Jan 15 |
|
Dependence of Ca2+-induced contraction on ATP in alpha-toxin-permeabilized preparations of rat femoral artery. | 2003 Oct |
|
Inhibition by cytoplasmic nucleotides of a new cation channel in freshly isolated human and rat type II pneumocytes. | 2004 Dec |
|
Ranolazine improves abnormal repolarization and contraction in left ventricular myocytes of dogs with heart failure by inhibiting late sodium current. | 2006 May |
|
Acylation with diangeloyl groups at C21-22 positions in triterpenoid saponins is essential for cytotoxicity towards tumor cells. | 2007 Feb 1 |
|
Intracellular calcium stores in beta-escin skinned rat and guinea-pig bladders. | 2007 Jul 2 |
|
Dynamic modulation of intracellular glucose imaged in single cells using a FRET-based glucose nanosensor. | 2008 May |
|
Beta-escin, a natural triterpenoid saponin from Chinese horse chestnut seeds, depresses HL-60 human leukaemia cell proliferation and induces apoptosis. | 2008 Sep |
|
Liquid chromatography/tandem mass spectrometry method for the quantification of deserpidine in human plasma: Application to a pharmacokinetic study. | 2009 Oct 1 |
|
Brain Activation by Peptide Pro-Leu-Gly-NH(2) (MIF-1). | 2010 |
|
Calcium sensitization induced by sodium fluoride in permeabilized rat mesenteric arteries. | 2010 Feb |
|
Identification of beta-escin as a novel inhibitor of signal transducer and activator of transcription 3/Janus-activated kinase 2 signaling pathway that suppresses proliferation and induces apoptosis in human hepatocellular carcinoma cells. | 2010 Jul |
|
Beta-escin has potent anti-allergic efficacy and reduces allergic airway inflammation. | 2010 May 21 |
|
KMUP-1 ameliorates monocrotaline-induced pulmonary arterial hypertension through the modulation of Ca2+ sensitization and K+-channel. | 2010 May 8 |
|
Parameters of Reserpine Analogs That Induce MSH2/MSH6-Dependent Cytotoxic Response. | 2010 Sep 13 |
Patents
Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 10:06:41 GMT 2023
by
admin
on
Sat Dec 16 10:06:41 GMT 2023
|
Record UNII |
6LPC48045D
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
73425400
Created by
admin on Sat Dec 16 10:06:41 GMT 2023 , Edited by admin on Sat Dec 16 10:06:41 GMT 2023
|
PRIMARY | |||
|
6033-69-8
Created by
admin on Sat Dec 16 10:06:41 GMT 2023 , Edited by admin on Sat Dec 16 10:06:41 GMT 2023
|
PRIMARY | |||
|
DBSALT002253
Created by
admin on Sat Dec 16 10:06:41 GMT 2023 , Edited by admin on Sat Dec 16 10:06:41 GMT 2023
|
PRIMARY | |||
|
DTXSID10387112
Created by
admin on Sat Dec 16 10:06:41 GMT 2023 , Edited by admin on Sat Dec 16 10:06:41 GMT 2023
|
PRIMARY | |||
|
6LPC48045D
Created by
admin on Sat Dec 16 10:06:41 GMT 2023 , Edited by admin on Sat Dec 16 10:06:41 GMT 2023
|
PRIMARY | |||
|
m4189
Created by
admin on Sat Dec 16 10:06:41 GMT 2023 , Edited by admin on Sat Dec 16 10:06:41 GMT 2023
|
PRIMARY | Merck Index |
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |